-
2022-502010-85-00
9
2023-12-20
Non-Squamous Non-Small Cell Lung Cancer
-
2022-502593-17-00
5
2023-09-19
Locally advanced or metastatic hormone receptor (HR)-positive, human e
-
2022-502322-41-00
5
2023-09-12
Metastatic breast cancer
-
2023-508462-15-00
10
2023-04-27
Narcolepsy with Cataplexy (Narcolepsy Type 1)
-
2023-505552-22-00
5
2023-02-24
Stage I-III Triple-negative Breast Cancer with residual invasive disea
-
2024-512915-33-00
5
2022-12-22
Metastatic Colorectal Cancer
-
2023-509825-38-00
5
2022-12-01
Metastatic Non–Small Cell Lung Cancer
-
2023-505772-30-00
5
2022-11-09
Melanoma
-
2023-504195-14-00
5
2022-08-31
PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
-
2022-500014-26-00
5
2022-06-24
Locally-Advanced unresectable or Metastatic breast cancer (MBC)
-
2023-506771-10-00
5
2022-03-11
Breast Neoplasm, Neoplasm Metastasis
-
2023-505454-18-00
5
2021-11-24
Erosive Esophagitis
-
2024-516543-26-00
5
2021-07-23
Type 1 Diabetes Mellitus
-
2023-505249-24-00
5
2021-05-27
HER2-positive metastatic breast cancer
-
2023-503995-26-00
5
2021-05-11
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
-
2023-503568-18-00
5
2021-04-13
Early human epidermal growth factor receptor 2 (HER2) positive breast
-
2023-506413-22-00
5
2021-03-31
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
-
2024-516554-22-00
4
2021-03-29
Locally-advanced stage II-III rectal cancer
-
2022-502600-79-00
4
2021-03-16
Endometrial cancer
-
2024-516653-44-00
5
2020-11-30
HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
-
2023-507153-16-00
5
2020-11-18
Higher-Risk Myelodysplastic Syndrome
-
2024-514733-38-00
5
2020-11-03
Unresectable locally-advanced or metastatic HER2+ breast cancer
-
2023-510390-33-00
5
2020-10-23
HER2-negative breast cancer patients with high relapse risk after
stan
-
2023-506365-64-00
5
2020-10-16
Deleterious Germline or Somatic Homologous Recombination Repair (HRR)